Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8837-8844

  Fujita, Tomoyuki ^a   Ito, Ken Ichi ^a   Izumi, Hiroto ^b   Kimura, Morihiko ^c   Sano, Muneaki ^d   Nakagomi, Hiroshi ^e   Maeno, Kazuma ^a   Hama, Yoshihisa ^a   Shingu, Kiyoshi ^a   Tsuchiya, Shin Ichi ^f   Kohno, Kimitoshi ^b   Fujimori, Minoru ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c GUNMA PREFECTURAL CANCER CENTER   (Japan)

^d NIIGATA CANCER CENTER HOSPITAL   (Japan)

^e Yamanashi Prefectural Central Hospital   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; Y BOX BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL NUCLEUS; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG RESISTANCE; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIDE EFFECT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; P-GLYCOPROTEIN; PACLITAXEL; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; UP-REGULATION; Y-BOX-BINDING PROTEIN 1;

EID: 29344434259     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0945     Document Type: Article

References (24)

1. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced nonsmall-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with pactitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
4. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-4.
5. Einzig AI, Wiernik PH, Schwartz EL. Taxol: a new agent active in melanoma and ovarian cancer. Cancer Treat Res 1991;58:89-100.
6. Abrams JS, Vena DA, Baltz J, et al, Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13:2056-65.
7. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
8. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
9. Furukawa M, Uchiumi T, Nomoto M, et al. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIα gene by heat shock. J Biol Chem 1998;273:10550-5.
10. Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-4.
11. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
12. Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447-50.
13. Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998;4:2273-7.
14. Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999;85:2450-4.
15. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 1992;69:2603-9.
16. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer: recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Caner 2004;11:139-47.
17. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996;56:4224-8.
18. Okamoto T, Izumi H, Imamura T, et al. Direct interaction of p53 with theY-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000;19:6194-202.
19. Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-Box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999;59:342-6.
20. Kohno K, Izumi H, Uchiumi T, et al. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003;25:691-8.
21. Saji H, Toi M, Saji S, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003;190:191-7.
22. Yahata H, Kobayashi H, Kamura T, et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer J Cancer Res Clin Oncol 2002;128:621-6.
23. Janz M, Harbeck N, Dettemar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97:278-82.
24. Stein U, Jurchott K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001;276:28562-9.